Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome

Leukemia and Lymphoma

Volumn 50, Issue 9, 2009, Pages 1461-1467

  Wu, Lingyun ^a   Li, Xiao ^a   Su, Jiying ^a   Chang, Chunkang ^a   He, Qi ^a   Zhang, Xi ^a   Xu, Li ^a   Song, Luxi ^a   Pu, Quan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

cytarabine; granulocyte colony stimulating factor (G CSF); homoharringtonine; Myelodysplastic syndromes; priming

Indexed keywords

ACLARUBICIN; CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HOMOHARRINGTONINE; IDARUBICIN; MITOXANTRONE; PIRARUBICIN; ANTINEOPLASTIC AGENT; HARRINGTONINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTOPENIA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; RELAPSE; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE COUNT; TRANSFORMED ACUTE MYELOID LEUKEMIA; TREATMENT RESPONSE; VOMITING; ADJUVANT THERAPY; CELL TRANSFORMATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL TRANSFORMATION, NEOPLASTIC; CYTARABINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOADJUVANT THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953512425     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903096719     Document Type: Article

References (34)

1. Hoyle CF, de Bastos M, Wheatley K, et al. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br J Haematol 1989;72:45-53. (Pubitemid 19133767)
2. Oosterveld M, Muus P, Suciu S, et al. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia: two parallel studies adjusted for various prognostic factors. Leukemia 2002;16:16151-16621.
3. Graf M, Hecht K, Reif S, et al. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol 2003;72:89-106. (Pubitemid 38161157)
4. te Boekhorst PA, Löwenberg B, Vlastuin M, et al. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 1993;7:1191-1198. (Pubitemid 23256468)
5. Te Boekhorst PA, Löwenberg B, Sonneveld P. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 1994;8:1480-1486. (Pubitemid 24293652)
6. Bai A, Kojima H, Hori M, et al. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol 1999;27:259-265. (Pubitemid 29131737)
7. Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia 1995;9:10-14.
8. Qian SX, Li JY, Tian T, et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colonystimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res 2007;31:1383-1388. (Pubitemid 47212427)
9. Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colonystimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 2000;71:238-244.
10. Takemura Y, Ohnuma T, Chou TC, et al. Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells. Cancer Chemother Pharmacol 1985;14:206-210. (Pubitemid 15118639)
11. Zhou JY, Chen DL, Shen ZS, et al. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 1990;50:2031-2035.
12. Jie H, Donghua H, Xingkui X, et al. Homoharringtonineinduced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway. Leuk Lymphoma 2007;48:964-977. (Pubitemid 47161569)
13. Mai WY, Lin MF. Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells. Chin Med J 2005;118:487-492.
14. Ye XJ, Lin MF. Homoharringtonine induces apoptosis of endothelium and down-regulates VEGF expression of K562 cells. J Zhejiang Univ Sci 2004;5:230-234.
15. Fresno M, Jimenez A, Vazqueq D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 1977;72:323-330. (Pubitemid 8022231)
16. Huang MT. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 1975;11:511-519.
17. Smith CR Jr, Powell RG, Mikolajczak KL. The genus Cephalotaxus: source of homoharringtonine and related anticancer alkaloids. Cancer Treat Rep 1976;60:1157-1170.
18. Cephalotaxus Research Coordinating Group. Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J 1976;2:263-272.
19. Kantarjian HM, Keating MJ, Walters RS, et al. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 1989;63:813-817. (Pubitemid 19063182)
20. Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 1992;6:1185-1188.
21. Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia 1992;6:1189-1191.
22. Feldman EJ, Seiter KP, Ahmed T, et al. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 1996;10:40-42. (Pubitemid 26052977)
23. Fanucchi MP, Kong XR, Chou TC. Hexamethylene bisacetamide (HMBA) does not enhance the cytotoxic effects of adriamycin (ADR), 1, b-D- arabinofuranosylcytosine (ARA-C) and harringtonine (HT) in HL-60 cells [Abstract 1492]. Proc Am Assoc Cancer Res 1986;27:376.
24. Löwenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743-752. (Pubitemid 37010778)
25. Delacretaz F, Schmidt PM, Piguet D, et al. Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol 1987;87:180-186. (Pubitemid 17022456)
26. ISCN (International System for Human Cytogenetic Nomenclature). Guidelines for cancer cytogenetics. In: Mitelman F, editor. Supplement to an International System for Human Cytogenetic Nomenclature. Basel: Karger; 1991. pp 1-53.
27. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088. (Pubitemid 27132124)
28. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-425. (Pubitemid 44061337)
29. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649. (Pubitemid 46594039)
30. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
31. Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine =cytosine arabinoside + idarubicin ± alltrans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999;93:2478-2484. (Pubitemid 29181178)
32. Hamblin TJ. Intensive chemotherapy in myelodysplastic syndromes. Blood Rev 1992;3:215-219. (Pubitemid 23003428)
33. Jackson G, Taylor P, Smith GM, et al. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 2001;112:127-137. (Pubitemid 32151160)
34. Li JM, Shen Y, Wu DP, et al. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colonystimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients. Int J Hematol 2005;82:48-54. (Pubitemid 41512199)